10-Q: DuPont Reports Q2 2026 Growth Amidst Divestitures and Legal Matters

DuPont de Nemours, Inc. announced Q2 2026 results with a 4% increase in net sales driven by organic growth in both its Healthcare & Water Technologies and Diversified Industrials segments.

Summary

• DuPont de Nemours, Inc. reported Q2 2026 net sales of $1.819 billion, a 4% increase year-over-year, driven by a 4% rise in organic sales.
• For the first six months of 2026, net sales were $3.5 billion, up 4% from the prior year, with a 3% organic sales increase and a 1% favorable currency impact.
• Operating EBITDA for Q2 2026 was $471 million, an increase from $447 million in Q2 2025, with both Healthcare & Water Technologies and Diversified Industrials segments showing growth.
• The company completed the Aramids Divestiture on April 1, 2026, receiving $1.2 billion in cash and a $300 million note receivable.
• A reverse stock split of 1-for-3 became effective on June 24, 2026, with all share information retroactively adjusted.
• The company continues to manage significant legal and environmental liabilities, particularly related to PFAS, with ongoing accruals and settlements.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting solid revenue growth and improved operating EBITDA, despite ongoing legal and environmental liabilities.

Positives

• Net sales increased by 4% to $1.819 billion in Q2 2026 compared to Q2 2025, driven by a 4% increase in organic sales.
• Operating EBITDA for Q2 2026 was $471 million, up from $447 million in Q2 2025, indicating improved operational performance.
• The Healthcare & Water Technologies segment saw a 5% increase in net sales to $856 million in Q2 2026, with a 4% organic sales growth.
• The Diversified Industrials segment reported a 3% increase in net sales to $963 million in Q2 2026, driven by 3% organic sales growth.
• Cash provided by operating activities from continuing operations significantly increased to $632 million in the first six months of 2026 from $151 million in the prior year.
• The company has secured new revolving credit facilities totaling $2.75 billion, enhancing its liquidity.
• DuPont repurchased approximately 1.8 million shares in May 2026 as part of its $2 billion share repurchase program.

Negatives

• The company incurred a $44 million net loss from discontinued operations in Q2 2026, compared to a $46 million net income in Q2 2025.
• Total liabilities increased to $7.180 billion at June 30, 2026, from $7.472 billion at December 31, 2025, though total debt decreased.
• The company has significant ongoing accruals for legal and environmental matters, particularly related to PFAS, totaling $723 million in indemnification liabilities and $291 million in environmental remediation liabilities.
• Restructuring and asset-related charges amounted to $43 million for the six months ended June 30, 2026, compared to $39 million in the prior year period.
• Acquisition, integration, and separation costs were $7 million in Q2 2026, down from $55 million in Q2 2025, but still represent ongoing transaction-related expenses.

Risks

• Risks and costs related to the impact of the arrangement to share future eligible PFAS costs, including the outcome of pending or future litigation related to PFAS or PFOA.
• The failure to realize expected benefits and effectively manage anticipated synergies and operational efficiencies in connection with divestitures and other portfolio management actions.
• Risks and uncertainties outside the Company's control that adversely impact the overall operating environment, including changes in economic, political, regulatory, international trade, geopolitical, military conflicts, capital markets, and other external conditions.
• The ability to offset increases in the cost of inputs, including raw materials, energy, and logistics.
• Risks and uncertainties associated with continuing or expanding geopolitical conflicts or trade disputes or restrictions and responsive actions, new or increased tariffs or export controls.
• Risks and uncertainties in connection with completing the $2 billion share buyback announced on November 6, 2025, including timeline, associated costs, and the possibility that the authorization may be suspended or discontinued prior to completion.
• The impact of the invalidation of certain tariffs imposed under the International Emergency Economic Powers Act.
• Supply chain and operational disruptions, including those that affect the Company's customers and suppliers, could significantly increase costs and expenses, adversely impact sales and earnings, and impact access to sources of liquidity.

Future Outlook

The company expects its cash and cash equivalents, cash generated from operations, and ability to access the debt capital markets to provide sufficient liquidity and financial flexibility to meet its obligations. The company expects to continue paying quarterly dividends, subject to board approval. The 2026 DuPont Restructuring Program is expected to incur pre-tax charges of approximately $75 million and continue through 2028. The Transformational Separation-Related Restructuring Program is expected to be completed in 2026.

Management Comments

• DuPont's innovations power the essential products and technologies people rely on every day.
• The Company expects its cash and cash equivalents, cash generated from operations, and ability to access the debt capital markets to provide sufficient liquidity and financial flexibility to meet the liquidity requirements associated with its continuing operations.
• The Company expects to continue to pay quarterly dividends, although each dividend is subject to the approval of the Company's Board of Directors.
• The Company expects to continue to pay quarterly dividends, although each dividend is subject to the approval of the Companys Board of Directors.

Industry Context

StockSavvy.ai notes that DuPont's performance aligns with broader trends in the specialty chemicals sector, showing resilience in key segments like healthcare and water technologies despite macroeconomic uncertainties and ongoing portfolio adjustments through divestitures.

Comparison to Industry Standards

• While specific industry benchmarks for all of DuPont's diverse segments are not provided in the filing, the reported 4% net sales growth in Q2 2026 is a solid indicator of performance in a competitive specialty chemicals market.
• Competitors like 3M and Honeywell also operate in diversified industrial and materials sectors, and their quarterly results would provide a more direct comparison for segments like Diversified Industrials.
• The company's focus on Healthcare & Water Technologies aligns with industry growth drivers such as increased demand for medical devices, biopharmaceutical production, and water purification solutions, areas where companies like Danaher and Ecolab are also active.

Legal Proceedings

• The company is involved in various lawsuits, claims, and environmental actions including product liability, patent infringement, governmental regulation, contract and commercial litigation.
• Significant ongoing matters include those related to Per- and Polyfluoroalkyl Substances (PFAS), with substantial accruals and settlements, including a proposed Judicial Consent Order with the State of New Jersey and litigation in North Carolina.
• The company is a defendant in litigation concerning aqueous film-forming foams (AFFF) and related PFAS contamination, including a large multi-district litigation (MDL) with approximately 12,400 personal injury cases.
• A settlement was reached with a nationwide class of public water systems for $1.185 billion, of which DuPont contributed $408 million.
• The company is engaged in discussions with the EPA regarding alleged violations of the Resource Conservation and Recovery Act at its Spruance facility in Virginia.

Related Party Transactions

• The company has a note receivable of $300 million from Arclin related to the Aramids Divestiture, with interest income recognized.
• The company has a note receivable of $350 million from Derby Group Holdings LLC related to the Delrin divestiture, with interest income recognized.
• The company's financial results of Arclin will be included with a three-month lag using the equity method.
• The company's financial results of Derby are included with a three-month lag using the equity method.

Stakeholder Impact

• Shareholders: The reverse stock split may affect share price perception and trading dynamics. Ongoing share repurchases could increase shareholder value. Continued dividend payments provide income to shareholders.
• Creditors: The company's credit ratings remain investment-grade (BBB+/Baa1/BBB+), indicating continued access to debt markets, though covenants on credit facilities require monitoring.
• Suppliers: The company's complex global supply chains are subject to disruptions, which could impact raw material availability and costs, potentially affecting supplier relationships.
• Employees: Restructuring programs may lead to workforce adjustments. Stock-based compensation continues to be a component of employee incentives.
• Customers: The company's ability to meet demand and commitments could be impacted by supply chain disruptions. Continued innovation in Healthcare & Water Technologies and Diversified Industrials aims to meet customer needs.

Next Steps

• Continue to monitor macroeconomic conditions and geopolitical developments for potential impacts on financial condition and results of operations.
• Complete the 2026 DuPont Restructuring Program by the end of 2028.
• Complete the Transformational Separation-Related Restructuring Program in 2026.
• Continue to manage and resolve legal and environmental liabilities, particularly those related to PFAS.
• Execute the ongoing share repurchase program, with an expectation to repurchase $250 million in Q3 2026.

Key Dates

Recommendation

DuPont demonstrates solid operational performance with revenue and EBITDA growth, supported by strategic divestitures and share repurchases. However, significant ongoing legal and environmental liabilities, particularly concerning PFAS, introduce considerable uncertainty and risk that temper a more aggressive recommendation. The company's ability to effectively manage these liabilities and integrate its portfolio will be key to future value creation.

Keywords

DuPont, Quarterly Report, Form 10-Q, Financial Results, Healthcare Technologies, Diversified Industrials, Aramids Divestiture, Reverse Stock Split